Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Nelson

Showing results (371-380 of 519) with videos related to

Pageof 52
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 1985
Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitroL A Rubin, C C Kurman, M E Fritz, et al.
The British Journal of Psychiatry. Supplement|April 22, 1999
Olanzapine: a basic science updateF Bymaster, K W Perry, D L Nelson, et al.
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|September 1, 1996
The effects of an occupationally embedded exercise on bilaterally assisted supination in persons with hemiplegiaD L Nelson, K Konosky, K Fleharty, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 1998
Multiple subtypes of serotonin receptors are expressed in rat sensory neurons in cultureJ J Chen, M R Vasko, X Wu, et al.
Nature Immunology|September 29, 2001
Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding proteinW Liu, I Quinto, X Chen, et al.
The New Phytologist|May 16, 2021
Chloroplast quality control pathways are dependent on plastid DNA synthesis and nucleotides provided by cytidine triphosphate synthase twoKamran Alamdari, Karen E Fisher, David W Tano, et al.
The Journal of Clinical Psychiatry|January 1, 1997
In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drugF P Bymaster, K Rasmussen, D O Calligaro, et al.
Nature Genetics|January 1, 1993
Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndromeH L Hinds, C T Ashley, J S Sutcliffe, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1993
DOI and alpha-methylserotonin: comparative vascular and nonvascular smooth muscle effects and central 5-hydroxytryptamine2 receptor affinitiesM L Cohen, M P Johnson, K W Schenck, et al.
Human Molecular Genetics|March 1, 1994
Frequency and stability of the fragile X premutationA L Reiss, H H Kazazian, C M Krebs, et al.
Pageof 52

Showing results (371-380 of 519) with videos related to

Sort By:
Pageof 52
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 1985
Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitroL A Rubin, C C Kurman, M E Fritz, et al.
The British Journal of Psychiatry. Supplement|April 22, 1999
Olanzapine: a basic science updateF Bymaster, K W Perry, D L Nelson, et al.
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|September 1, 1996
The effects of an occupationally embedded exercise on bilaterally assisted supination in persons with hemiplegiaD L Nelson, K Konosky, K Fleharty, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 1998
Multiple subtypes of serotonin receptors are expressed in rat sensory neurons in cultureJ J Chen, M R Vasko, X Wu, et al.
Nature Immunology|September 29, 2001
Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding proteinW Liu, I Quinto, X Chen, et al.
The New Phytologist|May 16, 2021
Chloroplast quality control pathways are dependent on plastid DNA synthesis and nucleotides provided by cytidine triphosphate synthase twoKamran Alamdari, Karen E Fisher, David W Tano, et al.
The Journal of Clinical Psychiatry|January 1, 1997
In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drugF P Bymaster, K Rasmussen, D O Calligaro, et al.
Nature Genetics|January 1, 1993
Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndromeH L Hinds, C T Ashley, J S Sutcliffe, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1993
DOI and alpha-methylserotonin: comparative vascular and nonvascular smooth muscle effects and central 5-hydroxytryptamine2 receptor affinitiesM L Cohen, M P Johnson, K W Schenck, et al.
Human Molecular Genetics|March 1, 1994
Frequency and stability of the fragile X premutationA L Reiss, H H Kazazian, C M Krebs, et al.
Pageof 52